Novartis is pleased to announce the recommendation for use of its oral cancer drug Glivec (imatinib)* by NICE The National Institute for Clinical Excellence.
With this announcement, patients in England and Wales with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the blast crisis, accelerated phase or in chronic phase, who have been unsuccessfully treated with interferon-alpha therapy, will now have access to Glivec therapy.
Glivec is a molecularly targeted treatment for certain forms of CML, one of the four most common types of leukemia. “Novartis commends NICE for its decision to make Glivec available for CML patients in England and Wales,” said David Epstein, President, Novartis Oncology. “The decision is an important milestone which will allow this innovative drug to help patients battling this life-threatening disease.
This most recent decision by the NICE authorities adds to the growing number of government authorities that recognize the value and unprecedented efficacy of Glivec and are reimbursing it thus making it available to patients in their country.”
Worldwide, CML has an incidence of one-to-two cases per 100 000 population per year and is responsible for 15 to 20% of all adult cases of leukemia. In the United Kingdom, the incidence of CML is 1 1.5 per 100 000 of the population, with around 800 new patients diagnosed each year. NICE was established on 1 April 1999 as a Special Health Authority for England and Wales. It is part of the National Health Service (NHS) and its role is to promote high clinical standards in the NHS by developing or commissioning guidance on clinical and cost-effectiveness and disseminating guidance to clinicians, patients and commissioners.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!